Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04569942

Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

This multicentre, randomised controlled trial will enrol 1000 patients presenting with septic shock to the emergency department (ED) of participating hospitals in Australia and New Zealand. Participants will receive haemodynamic resuscitation with either a restricted fluids and early vasopressor regimen or a larger initial IV fluid volume with later introduction of vasopressors if required. Clinical care including the type of resuscitation fluid and vasopressor agent, will otherwise be in accordance with accepted standard care and according to clinician discretion. The study intervention will be delivered for at least 6 hours and up to 24 hours post-randomisation. Participants will be followed for up to 12 months and outcomes analysed on an intention-to-treat basis.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Bankstown Hospital, Bankstown, New South Wales, Australia

Loading trial locations.

About this study

The ARISE FLUIDS study is a multicentre, randomised, parallel group clinical trial of a restricted fluids and early vasopressor strategy compared to a larger initial IV fluid volume and later vasopressors for the haemodynamic resuscitation of patients with septic shock presenting to the ED. It will be conducted in hospitals in Australia and New Zealand with 1000 patients recruited over a 3-year period.

Each patient meeting all of the inclusion and none of the exclusion criteria will be randomised to receive haemodynamic resuscitation using either a restricted fluid and early vasopressor regimen (vasopressors arm) or a larger initial fluid resuscitation volume (fluids arm) followed by later introduction of vasopressors (if required). The intervention will be commenced in the ED and delivered for at least 6 hours, and up to 24 hours post-randomisation if admitted to the ICU or other critical care area where the study protocol can be faithfully delivered. Treatment will revert to usual care as determined by the treating clinician when the patient is transferred to a non-critical care ward. All enrolled participants will be followed up and assessed for the defined study outcomes.

Participants will be identified using a systematic approach to screening and assessment of patients with possible sepsis presenting to the ED in accordance with standard clinical practice.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically suspected infection;
  • Systolic blood pressure (SBP) <90 mm Hg or mean arterial pressure (MAP) <65 mm Hg, despite a ⩾1000ml cumulative total bolus of IV fluid administered over a maximum of 60 minutes; including pre-hospital boluses;
  • Arterial or venous blood lactate >2.0 mmol/L;
  • At least one dose of an intravenous antimicrobial has been commenced.

Exclusion criteria

  • Age <18 years;
  • Confirmed or suspected pregnancy;
  • Transferred from another acute care facility;
  • Hypotension suspected to be due to a non-sepsis cause;
  • >2L total IV fluid administered (including prehospital fluids but excluding drugs and flushes);
  • More than 6 hours has elapsed since presentation to the ED or more than 2 hours has elapsed since last inclusion criterion has been met;
  • Treating clinician considers that one or both of the treatment regimens are not suitable for the patient or the study protocol cannot be delivered e.g. limitation of care, requirement for immediate surgery;
  • Death is considered imminent or inevitable;
  • Underlying disease that makes survival to 90 days unlikely;
  • Inability to follow patient up to day-90 e.g. unstable accommodation, overseas visitor;
  • Previously enrolled in this study.

Treatment and study plan

Vasopressor

Drug

Cease IV fluid resuscitation. If persisting hypotension and/or hypoperfusion commence a vasopressor infusion (e.g. noradrenaline) and titrate according to local practice to achieve target MAP. The target MAP will be determined by the treating clinician. Reassess at least hourly for up to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Boluses of 250ml of IV fluids are permitted if deemed indicated by the treating clinician.

Fluids

Other

An fluid bolus of up to 1000ml will be administered over a maximum of 1 hour, if required, for persisting hypotension and/or hypoperfusion. Reassess at least hourly to 6 hours post-randomisation, then as clinically required in conjunction with the protocol. Further IV fluid boluses of 500ml are recommended as clinically indicated to achieve the target MAP. The target MAP will be determined by the treating clinician. Haemodynamic resuscitation will be guided by usual clinical assessment including vital signs, mentation, perfusion, and urine output until the treating clinician determines fluid resuscitation is no longer clinically required. A minimum of 2-3 L (30 ml/kg), including pre-randomisation fluids, is recommended within 3 hours of ED arrival consistent with the SSC guidelines, unless clinically contraindicated. Vasopressors may be commenced if blood pressure remains below target despite optimal fluid resuscitation as determined by the treating clinician.

Primary outcomes

  1. Days alive and out of hospital

    Time frame: From randomisation until 90 days post- randomization

    the number of days alive and out of hospital at 90 days post randomization

Secondary outcomes

  1. Mortality

    Time frame: From randomisation until 90 days post- randomization

    All-cause mortality

  2. Time from randomization until death

    Time frame: From randomisation until 90 days post- randomization

    Time from randomization until death

  3. Days alive and at home

    Time frame: From randomisation until 90 days post- randomization

    Days alive and at home at 90 days post-randomisation

  4. Ventilator-free days to day 28

    Time frame: From randomisation until 28 days post- randomization

    Number of days not on invasive mechanical ventilation

  5. Vasopressor-free days to day 28

    Time frame: From randomisation until 28 days post- randomization

    Number of days not on vasopressors

  6. Renal replacement therapy-free days to day 28

    Time frame: From randomisation until 28 days post- randomization

    Number of days not on renal replacement therapy

  7. Death or disability at 6 months

    Time frame: at 6 months post randomization

    Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)

  8. Death or disability at 12 months

    Time frame: at 12 months post randomization

    Death or disability as measured by the World Health Organization Disability Assessment Schedule (WHODAS)

Other outcomes

  1. Incidence of invasive mechanical ventilation

    Time frame: From randomisation until 90 days post- randomization

    Incidence of invasive mechanical ventilation

  2. Duration of invasive mechanical ventilation

    Time frame: From randomisation until 90 days post- randomization

    Duration of invasive mechanical ventilation

  3. Incidence of acute renal replacement therapy

    Time frame: From randomisation until 90 days post- randomization

    Incidence of acute renal replacement therapy

  4. Duration of acute renal replacement therapy

    Time frame: From randomisation until 90 days post- randomization

    Duration of acute renal replacement therapy

  5. Incidence of vasopressor support

    Time frame: From randomisation until 90 days post- randomization

    Incidence of vasopressor support

  6. Duration of vasopressor support

    Time frame: From randomisation until 90 days post- randomization

    Duration of vasopressor support

  7. Emergency Department length of stay

    Time frame: From randomisation until 90 days post- randomization

    Emergency Department length of stay

  8. Intensive care unit length of stay

    Time frame: From randomisation until 90 days post- randomization

    Intensive care unit length of stay

  9. Hospital length of stay

    Time frame: From randomisation until 90 days post- randomization

    Hospital length of stay

  10. In hospital mortality

    Time frame: From randomisation until 90 days post- randomization

    Patients who die in hospital

  11. Mortality at 6 months

    Time frame: 6 Months post- randomization

    mortality at 6 months

  12. Mortality at 12 months

    Time frame: 1 year post- randomization

    mortality at 12 months

  13. Quality of life at 6 months

    Time frame: 6 months post- randomization

    Patient quality of life as measured by the EuroQol Group 5 dimensions 5 levels survey (EQ-5D-5L)

  14. Quality of life at 12 months

    Time frame: 1 year post- randomization

    Patient quality of life as measured by the EuroQol Group 5 dimensions 5 levels survey (EQ-5D-5L)

  15. Cost-effectiveness measured as cost/quality-adjusted life year (QALY)

    Time frame: 1 year post- randomization

    cost effectiveness measured as cost per quality-adjusted life year

Sponsors and collaborators

Lead sponsor

Australian and New Zealand Intensive Care Research Centre

Other

Registry information

Acronym: ARISE FLUIDS

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Sep 30, 2020
Registry last updated
Mar 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.